Miletich J P, Majerus D W, Majerus P W
J Clin Invest. 1978 Oct;62(4):824-31. doi: 10.1172/JCI109194.
Human platelets have binding sites for plasma coagulation Factor X(a) that are available only after the platelet release reaction. Platelets from 15 normal donors bound 216+/-52 (SD) molecules of Factor X(a) per platelet. The association of Factor X(a) with its platelet surface receptor results in a 300,000-fold increase in the catalytic activity of Factor X(a) in forming thrombin from prothrombin. The turnover number for platelet-bound Factor X(a) was 1,850+/-460 mol thrombin/ml per min per mol Factor X(a) in experiments with platelets from 15 normal donors. Platelets from five patients with varying degrees of Factor V deficiency were investigated to determine whether or not coagulation Factor V participates in either aspect of the Factor X(a)-platelet interaction. The binding of Factor X(a) to platelets and the accompanying increase in rate of thrombin formation were either reduced in parallel or absent in each case with values ranging from 0 to 45% of control values. The apparent affinity of Factor X(a) from Factor V-deficient patients was normal when platelet binding was detected. The supernate from thrombin-treated control platelets, which contains Factor V activity, corrected the Factor X(a) binding deficiency of the platelets from three patients tested. Immunoreactive Factor V determined with an homologous antibody corresponded to the functional Factor V activity of platelets from one patient with Factor V deficiency, suggesting that the patient's platelets have a decreased amount of normal Factor V. The ability of platelets from the patients to bind Factor X(a) and increase the rate of thrombin formation correlated with the severity of each patient's bleeding disorder better than the plasma level of Factor V. The results indicate that Factor V is required for the Factor X(a)-platelet interaction and that thrombin formation at the platelet surface is important in normal hemostasis.
人血小板具有血浆凝血因子X(a)的结合位点,这些位点仅在血小板释放反应后才可用。来自15名正常供体的血小板每个血小板结合216±52(标准差)个因子X(a)分子。因子X(a)与其血小板表面受体的结合导致因子X(a)从凝血酶原形成凝血酶的催化活性增加30万倍。在对来自15名正常供体的血小板进行的实验中,血小板结合的因子X(a)的转换数为每分钟每摩尔因子X(a)1850±460摩尔凝血酶/毫升。研究了五名不同程度因子V缺乏患者的血小板,以确定凝血因子V是否参与因子X(a)-血小板相互作用的任何一个方面。因子X(a)与血小板的结合以及随之而来的凝血酶形成速率的增加在每种情况下要么平行降低,要么不存在,其值范围为对照值的0%至45%。当检测到血小板结合时,来自因子V缺乏患者的因子X(a)的表观亲和力正常。凝血酶处理的对照血小板的上清液含有因子V活性,纠正了三名受试患者血小板的因子X(a)结合缺陷。用同源抗体测定的免疫反应性因子V与一名因子V缺乏患者血小板的功能性因子V活性相对应,表明该患者的血小板中正常因子V的量减少。患者血小板结合因子X(a)并增加凝血酶形成速率的能力与每个患者出血性疾病的严重程度相关性比因子V的血浆水平更好。结果表明,因子V是因子X(a)-血小板相互作用所必需的,并且血小板表面的凝血酶形成在正常止血中很重要。